MIST
NASD Milestone Pharmaceuticals, Inc.$0.7121 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.7121, $0.0569 below the day’s high of $0.7690
- YTD change
- -64.75%
- vs 20-day SMA
- -17.79%
- vs 200-day SMA
- -52.07%
Price ranges
Price & Performance
-1.07 (-59.99%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 97.5% away from all-time highs of $27.9500
- MIST is down 65% since the beginning of the year
- MIST is down 64% over the past 12 months
- MIST is down 33% over the past 1 month
- 15% of all MIST investors are betting against MIST
MIST reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -64.4%.
- Previous minute
- -$0.0002
- Last hour
- +$0.0005
- Last 5 days
- -17.74%
- vs 8-day SMA
- -11.09%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
